Contents
- The progression from unopposed estrogen to cancer
- Risk factors and protective factors
- The postmenopausal bleeding work-up
- Management by biopsy result
- FIGO 2023 staging in brief
- Lynch syndrome and endometrial cancer
- Clue in the stem, next best step
- Where students lose points
- Practice question
- 60-second recall
- Sources
Endometrial cancer questions on the OB-GYN shelf almost always begin with bleeding: a postmenopausal woman with spotting, an obese woman with irregular heavy periods, or a patient on tamoxifen. The question is rarely the diagnosis. It is the next step in the workup, or the treatment of what the biopsy shows.
The progression from unopposed estrogen to cancer
- Unopposed estrogenObesity, anovulation, estrogen-only therapy, tamoxifen
- Hyperplasia without atypiaLow cancer risk; progestin
- Atypical hyperplasia (EIN)Precancer; hysterectomy
- Endometrioid carcinomaUsually low grade and early stage
This is the classic estrogen-driven (type I) path, behind most endometrial cancers. The second group, the non-endometrioid or type II cancers (serous and clear cell carcinoma), arises in atrophic endometrium in older women, is often p53-abnormal, and spreads early.
Risk factors and protective factors
| Raises risk | Why | Lowers risk |
|---|---|---|
| Obesity | Adipose tissue converts androgens to estrone | Combined hormonal contraception |
| Chronic anovulation, including PCOS | Estrogen without cyclic progesterone | Progestin therapy, including the levonorgestrel IUD |
| Estrogen-only therapy with an intact uterus | Unopposed estrogen | Adding a progestin to menopausal estrogen |
| Tamoxifen | Estrogen agonist in the endometrium | Parity |
| Early menarche, late menopause, nulliparity | Longer estrogen exposure | |
| Lynch syndrome | Mismatch repair deficiency | |
| Diabetes, older age | Associated factors |
The postmenopausal bleeding work-up
About 90% of patients with endometrial cancer present with abnormal bleeding, so any postmenopausal bleeding is evaluated.
- Take every episode seriouslyOne episode of spotting after menopause is enough to start the workup.
- Transvaginal ultrasound and endometrial sampling togetherIn April 2026, ACOG updated its guidance: for most patients, the initial evaluation combines transvaginal ultrasound with endometrial tissue sampling, usually an office biopsy.
- Do not let a thin stripe close the caseAn endometrial thickness of 4 mm or less is no longer enough on its own to exclude cancer in most patients. Aggressive non-endometrioid cancers may not thicken the stripe, and fibroids often make the endometrium hard to see.
- Persistent bleeding or a nondiagnostic biopsyHysteroscopy with directed biopsy, or dilation and curettage.
- Treat by the pathologyHyperplasia, atypical hyperplasia or cancer, as below.
Sources differ here: older question banks and the 2018 ACOG opinion allowed ultrasound alone, with no biopsy, when the endometrium measured 4 mm or less. The 2026 update replaced that triage rule for most patients. If an exam question offers both, the safest answer is the one that gets tissue.
Management by biopsy result
| Biopsy shows | Management |
|---|---|
| Hyperplasia without atypia | Progestin (levonorgestrel IUD or oral), remove the estrogen source, repeat sampling |
| Atypical hyperplasia (endometrial intraepithelial neoplasia) | Total hysterectomy; a concurrent cancer is often present. Progestin is the alternative for patients who want fertility or cannot have surgery |
| Endometrial carcinoma | Surgical staging: total hysterectomy, bilateral salpingo-oophorectomy and sentinel lymph node mapping, often minimally invasive. Test every tumor for mismatch repair status |
FIGO 2023 staging in brief
- Stage I: confined to the uterine corpus. Aggressive histology (serous, clear cell, high-grade endometrioid, carcinosarcoma) without myometrial invasion is IC.
- Stage II: cervical stromal invasion, substantial lymphovascular invasion in a non-aggressive type, or an aggressive type with any myometrial invasion (IIC).
- Stage III: local or regional spread: adnexa or serosa, vagina or parametria, pelvic or para-aortic nodes.
- Stage IV: bladder or bowel mucosa, extrapelvic peritoneum, or distant metastasis.
- Molecular class: FIGO encourages POLE, mismatch repair, p53 and NSMP classification for all tumors. In stage I and II, a POLE mutation downstages to IAm, and p53-abnormal tumors with myometrial invasion are upstaged to IICm.
Lynch syndrome and endometrial cancer
Endometrial cancer is often the first cancer in women with Lynch syndrome. Mismatch repair testing of every endometrial cancer finds these families. For known carriers, the ACG suggests offering endometrial cancer screening with endometrial sampling from age 30 to 35, and discussing risk-reducing hysterectomy with bilateral salpingo-oophorectomy once childbearing is complete.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| 64-year-old with one episode of spotting, BMI 37 | Postmenopausal bleeding | Transvaginal ultrasound and endometrial biopsy |
| Woman on tamoxifen for breast cancer with new bleeding | Tamoxifen-related endometrial pathology | Endometrial sampling |
| 35-year-old with PCOS, irregular heavy bleeding, BMI 34 | Chronic anovulation with unopposed estrogen | Endometrial biopsy; age alone does not exclude it |
| Biopsy shows atypical hyperplasia, childbearing complete | Precancer with a high rate of concurrent cancer | Total hysterectomy |
| Atypical hyperplasia, 29 years old, wants pregnancy | Fertility-sparing case | High-dose progestin (often a levonorgestrel IUD) with repeat sampling |
| Endometrial cancer at 44, father had colon cancer at 46 | Lynch syndrome | Mismatch repair testing and genetic counseling |
| Nondiagnostic office biopsy, bleeding continues | Inadequate sample | Hysteroscopy with directed biopsy |
Where students lose points
- Reassuring a patient with postmenopausal bleeding because the stripe is 4 mm or less. Under the 2026 ACOG update, most patients get tissue sampling as well.
- Waiting for a second episode of postmenopausal bleeding before evaluating.
- Skipping the biopsy in a premenopausal patient under 45 who has years of unopposed estrogen.
- Treating atypical hyperplasia with observation, or treating hyperplasia without atypia with hysterectomy as the default.
- Ordering Pap testing or CA-125 to diagnose endometrial cancer. Neither replaces endometrial sampling.
- Forgetting mismatch repair testing, which identifies Lynch syndrome in the patient's family.
Practice question
A 61-year-old woman comes to the office because of vaginal spotting on three occasions over the past 2 months. Menopause occurred at age 52. She takes no hormone therapy. She has type 2 diabetes and hypertension, and her BMI is 36 kg/m². Pelvic examination shows a normal cervix and a normal-sized uterus. A cervical screening test 1 year ago was normal. Transvaginal ultrasound shows an endometrial thickness of 3 mm.
Which of the following is the most appropriate next step?
- Reassurance and follow-up in 6 months
- Endometrial biopsy
- Serum CA-125
- Vaginal estrogen cream
- Total hysterectomy
Show the answer
Answer: B. She has recurrent postmenopausal bleeding and risk factors for endometrial cancer. Recurrent bleeding has always called for tissue sampling regardless of endometrial thickness, and the 2026 ACOG update now pairs ultrasound with tissue sampling for most patients at the first evaluation.
Why the others are wrong. A: a thin endometrium does not exclude cancer, especially with persistent bleeding. C: CA-125 is not a diagnostic test for endometrial cancer. D: treating presumed atrophy without tissue risks missing a cancer. E: hysterectomy is not done before a tissue diagnosis.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
1Most common presenting sign
Abnormal or postmenopausal bleeding (about 90%).Did you get it?22026 ACOG workup
Transvaginal ultrasound plus endometrial sampling for most patients.Did you get it?3Hyperplasia without atypia
Progestin.Did you get it?4Atypical hyperplasia (EIN)
Hysterectomy.Did you get it?5Type II tumors
Serous or clear cell, atrophic endometrium, p53-abnormal, aggressive.Did you get it?6FIGO 2023
Molecular class can downstage (POLE) or upstage (p53-abnormal).Did you get it?7Every endometrial cancer
Mismatch repair testing.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review the cervical cancer study guide, or see MedRise for students.
Sources
- American College of Obstetricians and Gynecologists. Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding. Clinical Practice Update. Obstet Gynecol, 2026 (PubMed 41990335)
- Cleveland Clinic Consult QD. New guidance supports dual assessment methods for postmenopausal bleeding, 2026
- American College of Obstetricians and Gynecologists. Endometrial intraepithelial neoplasia. Committee Opinion No. 631. Obstet Gynecol, 2015 (PubMed 25932867)
- Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet, 2023 (PubMed 37337978)
- Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 (PubMed 25645574)
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



